Compound repurposing
Small molecule compounds are being studied for repurposing in COVID-19 treament and research. Multiple small molecules that are approved to treat other disorders have shown potential effects on key proteins involved in SARS-CoV-2 host cell entry and replication. Repurposing of existing compounds is advantageous for speed - reducing timescales compared to conventional drug discovery. Researchers can save up to 50% on these small molecules for COVID-19 research, as they are up to half the price of other suppliers.
Calyculin A (HB0161)
Description:Potent, selective protein phosphatase 1 / 2A inhibitor
Purity:>98%
Cyclosporin A (HB0220)
Description:Potent calcineurin inhibitor. Inhibits MPTP opening.
Purity:>99%
DMSO (Sterile-filtered) (HB3262)
Description:Widely used solvent. Improves direct differentiation of pluripotent stem cells and used as a stem cell cryoprotectant
Purity:>99.9%
Doxycycline hyclate (HB4608)
Description:Broad-spectrum antibiotic. Used in inducible Tet-on/ Tet-off gene expression systems for gene editing.
Purity:>95%